Allogeneic hematopoietic cell transplantation in multiple myeloma

Jasleen Randhawa, Veerpal Singh, Parameswaran Hari

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Due to the inability to cure multiple myeloma (MM) with current therapies, including autologous stem cell transplantation (auto-SCT), there has been a sustained interest in allogeneic hematopoietic cell transplantation (allo-HCT) given its use of a myeloma-free donor cell graft and the possibility of a donor-driven, immune-mediated graft-versus-MM effect. This chapter begins with a discussion on the risks of allo-HCT in MM. Several randomized trials have attempted to evaluate the tandem auto-SCT-allo-HCT approach versus tandem auto-SCT in the upfront transplant setting. The chapter explains when allo-HCT can be offered in the disease course of MM. It also presents two case studies dealing with the genetically defined high-risk myeloma in a young patient and plasma cell leukemia (PCL). It concludes with a discussion on lenalidomide (LEN), and bortezomib.

Original languageEnglish (US)
Title of host publicationCancer Consult
Subtitle of host publicationExpertise for Clinical Practice
PublisherWiley
Pages381-387
Number of pages7
ISBN (Electronic)9781118589199
ISBN (Print)9781118589212
DOIs
StatePublished - Jun 20 2014

Keywords

  • Allogeneic hematopoietic cell transplantation (allo-HCT)
  • Autologous stem cell transplantation (auto-SCT)
  • Lenalidomide (LEN)
  • Multiple myeloma (MM)
  • Plasma cell leukemia (PCL)

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Allogeneic hematopoietic cell transplantation in multiple myeloma'. Together they form a unique fingerprint.

Cite this